Back to results
US 2026/0007731 A1Published application
Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same
AssigneeBlueWillow Biologics, Inc.
InventorsVira BITKO, Ali FATTOM, Shyamala GANESAN
Life of this patent
Estimating the term…
Abstract
The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.
Claims37
An intranasal bacterial vaccine composition comprising:
- (a) a polysaccharide-antigen conjugate comprising:
- (i) one or more polysaccharides from at least one polysaccharide-encapsulated bacteria, and
- (ii) a carrier protein covalently linked to one or more polysaccharides;
- and
- (b) a nanoemulsion adjuvant comprising:
- (i) droplets having an average diameter of less than about 1000 nm;
- (ii) an aqueous phase;
- (iii) about 1% to about 80% of at least one pharmaceutically acceptable oil;
- (iv) about 0.001% to about 10% of at least one surfactant, wherein the surfactant is a polyoxyethylene nonionic surfactant, a cationic quaternary ammonium compound, or a combination thereof;
- and
- (v) about 0.1% to about 50% of at least one organic solvent, wherein the organic solvent is an alcohol.
8 more elements
The intranasal bacterial vaccine composition of claim 2, wherein the composition comprises a panel of at least two polysaccharides from two different bacterial serotypes from the same bacterial genus and species.
Dependencies are inferred from the claim text.